Gender-based Differences in Patients with End-stage Heart Failure Referred for Heart Transplant and LVAD Evaluation

Authors

• Maria Obeidat, Michigan State University College of Human Medicine Medical Student
• Niharika Chinta, Michigan State University College of Human Medicine Medical Student
• Luke A. Laconi, Michigan State University College of Human Medicine Medical Student
• Joeita Macfield, Michigan State University College of Human Medicine Medical Student
• Anjali Purohit, Michigan State University College of Human Medicine Medical Student
• Dana Marsy, Corewell Health West
• Nabin Manandhar Shrestha, Corewell Health West
• Sangjin Lee, Corewell Health West
• Michael G. Dickinson, Corewell Health West
• David R. Fermin, Corewell Health West
• Matthew Gonzalez, Corewell Health West
• Ryan Grayburn, Corewell Health West
• Milena Jani, Corewell Health West
• Eesha Purohit, Corewell Health West
• Renzo Loyaga-Rendon, Corewell Health West

Document Type

Conference Proceeding

Publication Date

4-2026

Publication Title

Journal of the American College of Cardiology

Abstract

Background: Heart failure is a major cause of morbidity worldwide, with advanced stages often requiring referral for heart transplantation (HTx) or left ventricular assist device (LVAD). Data on sex disparities in patients evaluated for advanced heart failure (AHF) remain limited. This study aimed to assess differences in clinical characteristics and outcomes of patients referred for advanced therapies.

Methods: All patients referred to Corewell Health West for AHF therapies evaluation between 2009 and 2024 were included. Clinical characteristics and outcomes of the AHF evaluation were compared between genders.

Results: Of 1,199 patients, 894 (75%) were men and 305 (25%) women. Men were older (57.4 vs 54.2 years, p=0.003), more likely to be of White race (80.54% vs 67.87%; p< 0.01), and present with ischemic cardiomyopathy (49.33% vs 28.52%, p< 0.001) than women. Echocardiogram hemodynamics at evaluation showed a higher pulmonary capillary wedge pressure in men than women (p=0.012). There was a trend of women being evaluated less frequently for LVAD when compared to men (p=0.06). Less than 50% of patients evaluated were accepted for AHF, with no differences between genders (42.51% vs 42.62%, p=0.904). There were no gender differences in the therapy received.

Conclusion: At our center, men referred for AHF therapies were older, were more likely to be of White race, and presented with ischemic cardiomyopathy than females. There were no differences in evaluation outcome or therapy received between genders.

Volume

87

Issue

13 Suppl

First Page

A684

Comments

American College of Cardiology 75th Annual Scientific Session & Expo, March 28-30, 2026, New Orleans, LA

Last Page

A684

Recommended Citation

Obeidat M, Chinta N, Laconi LA, Macfield J, Purohit A, Marsy D, et al. [Shrestha NM, Lee S, Dickinson MG, Fermin DR, Gonzalez M, Grayburn R, Jani M, Purohit E, Loyaga-Rendon RY]. Gender-based differences in patients with end-stage heart failure referred for heart transplant and LVAD evaluation. J Am Coll Cardiol. 2026;87(13 Suppl):A684. doi:10.1016/j.jacc.2026.02.1790

DOI

doi:10.1016/j.jacc.2026.02.1790

ISSN

0735-1097